Plixorafenib

Plixorafenib (CAS No.: 1393466-87-9) is a synthetic small-molecule kinase inhibitor classified as a selective BRAF pathway modulator, used for systematic investigation of the RAS?RAF?MEK?ERK/MAPK signaling axis in biomedical and drug discovery contexts, and is particularly suitable for model systems carrying activating BRAF genetic alterations (such as point mutations or fusions); its mechanism of action is characterized by preferential inhibition of BRAF (with higher selectivity for mutant forms such as V600E, while retaining activity against wild-type BRAF and showing lower activity against CRAF), and by “paradox?breaking” properties that interfere with the assembly of BRAF-containing dimers, thereby reducing the paradoxical ERK activation commonly observed with first-generation RAF inhibitors in the context of co-expressed wild-type RAF; in in vitro studies, it shows nanomolar-level inhibitory effects on BRAF enzymatic activity and MAPK pathway signaling, with inhibition of cell proliferation and pathway downregulation typically in the single-digit to low double-digit nanomolar range, with specific activity affected by the assay method and target background; typical applications include dissecting oncogenic signaling dependency in BRAF mutation- or fusion-driven cell models, constructing and testing resistance mechanisms such as pathway reactivation mediated by splice variants or dimers, conducting methodological benchmark comparisons across different classes of RAF inhibitors, and performing combination screening with downstream MAPK inhibitors; in early-stage animal studies, it is commonly used to evaluate pharmacodynamic readouts such as pathway inhibition and target occupancy, as well as exposure?response relationships; the concentrations or doses used in experiments generally depend on the specific experimental design and research objectives; for research use only, not for human or veterinary purposes.